NATCO launches Bosentan Tablets for oral suspension in US with 180-day exclusivity
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
This acquisition expands HGM's healthcare platform capabilities in revenue cycle management
The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
Macitentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million
The accelerated approval is supported by results from part 1 of the ESSENCE trial
Subscribe To Our Newsletter & Stay Updated